Cardiotrophin 1
Also known as: Cardiotrophin-1, Cardiotrophin‑1, CT-1, CTF1, Cytokine CLCF1
Source Cardiotrophin 1 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Cardiotrophin‑1 (CT‑1) is a secreted cytokine involved in cardiac development and hypertrophic signaling. It is under investigation for potential therapeutic roles in heart failure and myocardial repair but has no approved clinical indication.
Mechanism of Action
Binds to a heterodimeric receptor complex composed of gp130 and LIFRβ, activating JAK/STAT, MAPK, and PI3K/Akt pathways leading to cardiomyocyte hypertrophy and survival.
Routes of Administration
Goals & Uses
- Cardiac hypertrophy induction (physiological)CardiologyModerate
- NeuroprotectionNeurologyLow
- Heart failure treatmentCardiovascularModerate
- Cardiac cytoprotectionCardiologyModerate
- Nonalcoholic fatty liver disease (NAFLD) treatmentHepatologyLow
- Cardiac hypertrophy modulationResearchModerate
- Heart failure therapyCardiovascularModerate
- Anti-obesity / metabolic regulationMetabolic DiseaseModerate
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Severe inflammatory conditions / sepsisImmunologyModerate
- Pre-existing pathological cardiac hypertrophyCardiologyModerate
Adverse Effects
- Injection site reactionsLocalUnknown
- HypotensionCardiovascularUnknownLow blood pressure
- Pro-inflammatory cytokine releaseImmunologicalUnknown
- Cardiac hypertrophyCardiovascularUnknown
Drug Interactions
- JAK inhibitors (e.g., ruxolitinib, tofacitinib)Moderate
- Anti-IL-6 receptor antibodies (e.g., tocilizumab)Moderate
- Cardiotoxic chemotherapeutic agents (e.g., doxorubicin)Low
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric populationsAgeRelative
- Patients with heart failure with preserved ejection fraction (HFpEF)CardiovascularRelative
- Immunocompromised patientsImmunologicRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization.
- United StatesUnapprovedInvestigational use only.
- United KingdomUnapprovedNo MHRA approval. Research molecule only.
No regulatory approval; used only in pre‑clinical and early clinical research.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Cardiotrophin 1?
Cardiotrophin‑1 (CT‑1) is a secreted cytokine involved in cardiac development and hypertrophic signaling. It is under investigation for potential therapeutic roles in heart failure and myocardial repair but has no approved clinical indication.
What is Cardiotrophin 1 used for?
Cardiotrophin 1 is educationally associated with: Cardiac hypertrophy induction (physiological), Neuroprotection, Heart failure treatment, Cardiac cytoprotection, Nonalcoholic fatty liver disease (NAFLD) treatment, Cardiac hypertrophy modulation, Heart failure therapy, Anti-obesity / metabolic regulation. Educational only — not medical advice.
How is Cardiotrophin 1 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Cardiotrophin 1?
Reported adverse effects include: Injection site reactions, Hypotension, Pro-inflammatory cytokine release, Cardiac hypertrophy. This list is not exhaustive — consult a qualified clinician.
Who should avoid Cardiotrophin 1?
Recorded contraindications: Active malignancy, Severe inflammatory conditions / sepsis, Pre-existing pathological cardiac hypertrophy. Consult a qualified clinician before use.